BONESUPPORT received market authorization from FDA for the company’s antibiotic eluting product CERAMENT G, for the indication bone infection (osteomyelitis).
CERAMENT G previously received Breakthrough Device Designation in 2021. As what is reportedly the first injectable combination antibiotic bone graft substitute, CERAMENT G can be delivered in a single-stage procedure to simultaneously support bone remodeling and locally elute Gentamicin to protect bone healing.
BONESUPPORT’s CERAMENT G is an implantable device/drug combination bone void filler that provides a pathway for a one-stage approach to the management of bone infection with its dual mode of action that delivers bone remodeling with reliable and safe local elution of a broad-spectrum antibiotic.
BONESUPPORT reports that CERAMENT technology has the largest amount of pre-clinical and clinical data to prove bone remodeling and is the only bone graft substitute technology with patient-reported outcome measures.
“This is a significant recognition for the power and promise of our technology, as we are the first-to-market in the U.S. with this breakthrough combination device/drug bone graft,” said Emil Billbaeck, CEO of BONESUPPORT. “Our years of success in Europe have validated the unique benefits and superior outcome that CERAMENT G brings – and we’re excited to address proven demand for a better way to treat patients with bone infections in the U.S. market.”
BONESUPPORT received market authorization from FDA for the company's antibiotic eluting product CERAMENT G, for the indication bone infection (osteomyelitis).
CERAMENT G previously received Breakthrough Device Designation in 2021. As what is reportedly the first injectable combination antibiotic bone graft substitute, CERAMENT G can be...
BONESUPPORT received market authorization from FDA for the company’s antibiotic eluting product CERAMENT G, for the indication bone infection (osteomyelitis).
CERAMENT G previously received Breakthrough Device Designation in 2021. As what is reportedly the first injectable combination antibiotic bone graft substitute, CERAMENT G can be delivered in a single-stage procedure to simultaneously support bone remodeling and locally elute Gentamicin to protect bone healing.
BONESUPPORT’s CERAMENT G is an implantable device/drug combination bone void filler that provides a pathway for a one-stage approach to the management of bone infection with its dual mode of action that delivers bone remodeling with reliable and safe local elution of a broad-spectrum antibiotic.
BONESUPPORT reports that CERAMENT technology has the largest amount of pre-clinical and clinical data to prove bone remodeling and is the only bone graft substitute technology with patient-reported outcome measures.
“This is a significant recognition for the power and promise of our technology, as we are the first-to-market in the U.S. with this breakthrough combination device/drug bone graft,” said Emil Billbaeck, CEO of BONESUPPORT. “Our years of success in Europe have validated the unique benefits and superior outcome that CERAMENT G brings – and we’re excited to address proven demand for a better way to treat patients with bone infections in the U.S. market.”
Copy to clipboard 
